Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nal-IRI) in the US.

Afsaneh Barzi,Rebecca A. Miksad,Andy Surinach,Frank A. Corvino,Siqi Wang,Aracelis Z. Torres,Khalid Mamlouk,Sonia Pulgar,Tanios S. Bekaii-Saab

Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nal-IRI) in the US.

2018

Afsaneh Barzi
Rebecca A. Miksad
Andy Surinach
Frank A. Corvino
Siqi Wang
Aracelis Z. Torres
Khalid Mamlouk
Sonia Pulgar
Tanios S. Bekaii-Saab

e16229Background: The NAPOLI-1 study, a randomized phase 3 study in patients with mPDAC previously treated with gemcitabine-based therapy, demonstrated an improvement in overall survival (OS), prog...

Keywords:

Metastatic pancreatic cancer
Oncology
Pathology
Liposomal Irinotecan
Medicine
Internal medicine
previously treated
Phases of clinical research
overall survival
in patient
real world outcomes
Gemcitabine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations